Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2014

Open Access 01-12-2014 | Research

Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy

Authors: Kunpeng Wu, Qiaozhu Yang, Yi Liu, Aibing Wu, Zhixiong Yang

Published in: World Journal of Surgical Oncology | Issue 1/2014

Login to get access

Abstract

Background

Triple-negative breast cancer (TNBC) is a special subtype of breast cancer that is characterized by poor prognosis, strong tumor invasion and a high pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC). The pCR rate is a prognostic factor for TNBC. We aimed to evaluate the relationship between pCR and TNBC after NAC and originally tried to identify factors related to achieving pCR for TNBC using a meta-analysis.

Methods

We systematically searched the literature for pCR and breast cancer after NAC and carefully identified eligibility criteria. The association between pCR and breast cancer subtypes was estimated using Review Manager, while pCR rates for TNBC and non-TNBC were determined using Meta-Analyst.

Results

This analysis included a total of 9,460 cases from 27 studies. The summary odds ratio estimating the relationship between pCR and breast cancer subtypes (TNBC vs non-TNBC) was 3.02 (95% confidence interval (CI), 2.66 to 3.42). The TNBC pCR rate was 28.9% (95% CI, 27.0 to 30.8%) and the non-TNBC was 12.5% (95% CI, 11.7 to 13.4%). From subgroup analyses, we identified the factors associated with the highest pCR rates for TNBC.

Conclusions

TNBC has a higher pCR rate than non-TNBC. In the NAC setting, these factors of platinum-containing, more than six cycles, four kinds of drugs, 16 weeks’ treatment duration and sequential chemotherapy may contribute to increasing the pCR rate.
Appendix
Available only for authorised users
Literature
1.
Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007, 13 (8): 2329-2334. 10.1158/1078-0432.CCR-06-1109.CrossRefPubMed
2.
Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007, 13 (15 Pt 1): 4429-4434.CrossRefPubMed
3.
Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA: Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat. 2009, 115 (2): 423-428. 10.1007/s10549-008-0086-2.CrossRefPubMed
4.
Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD: Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 2007, 7: 134-10.1186/1471-2407-7-134.PubMedCentralCrossRefPubMed
5.
Boyle P: Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol. 2012, 23 (Suppl 6): vi7-vi12.CrossRefPubMed
6.
Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, Hayes DF, Winer EP, Dressler L: Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res. 2006, 8 (6): R66-10.1186/bcr1622.PubMedCentralCrossRefPubMed
7.
Mieog JS, van der Hage JA, van de Velde CJ: Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev. 2007, 2: CD005002-PubMed
8.
Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005, 11 (16): 5678-5685. 10.1158/1078-0432.CCR-04-2421.CrossRefPubMed
9.
Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008, 26 (8): 1275-1281. 10.1200/JCO.2007.14.4147.CrossRefPubMed
10.
Kong X, Moran MS, Zhang N, Haffty B, Yang Q: Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer. 2011, 47 (14): 2084-2090. 10.1016/j.ejca.2011.06.014.CrossRefPubMed
11.
von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012, 30 (15): 1796-1804. 10.1200/JCO.2011.38.8595.CrossRefPubMed
12.
Goldstein NS, Decker D, Severson D, Schell S, Vicini F, Margolis J, Dekhne NS: Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer. 2007, 110 (8): 1687-1696. 10.1002/cncr.22981.CrossRefPubMed
13.
Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ: Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer. 2007, 7: 203-10.1186/1471-2407-7-203.PubMedCentralCrossRefPubMed
14.
Bidard FC, Matthieu MC, Chollet P, Raoefils I, Abrial C, Domont J, Spielmann M, Delaloge S, Andre F, Penault-Llorca F: p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. Ann Oncol. 2008, 19 (7): 1261-1265. 10.1093/annonc/mdn039.CrossRefPubMed
15.
Julka PK, Chacko RT, Nag S, Parshad R, Nair A, Oh DS, Hu Z, Koppiker CB, Nair S, Dawar R, Dhindsa N, Miller ID, Ma D, Lin B, Awasthy B, Perou CM: A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling. Br J Cancer. 2008, 98 (8): 1327-1335. 10.1038/sj.bjc.6604322.PubMedCentralCrossRefPubMed
16.
Sánchez-Muñoz A, García-Tapiador AM, Martínez-Ortega E, Dueñas-García R, Jaén-Morago A, Ortega-Granados AL, Fernández-Navarro M, Torre-Cabrera C, Dueñas B, Rueda AI, Morales F, Ramírez-Torosa C, Martín-Salvago MD, Sánchez-Rovira P: Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Clin Transl Oncol. 2008, 10 (10): 646-653. 10.1007/s12094-008-0265-y.CrossRefPubMed
17.
Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G, Johnston S, Smith IE: Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol. 2008, 19 (11): 1847-1852. 10.1093/annonc/mdn395.CrossRefPubMed
18.
Darb-Esfahani S, Loibl S, Muller BM, Roller M, Denkert C, Komor M, Schluns K, Blohmer JU, Budczies J, Gerber B, Noske A, du Bois A, Weichert W, Jackisch C, Dietel M, Richter K, Kaufmann M, von Minckwitz G: Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res. 2009, 11 (5): R69-10.1186/bcr2363.PubMedCentralCrossRefPubMed
19.
Sikov WM, Dizon DS, Strenger R, Legare RD, Theall KP, Graves TA, Gass JS, Kennedy TA, Fenton MA: Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. J Clin Oncol. 2009, 27 (28): 4693-4700. 10.1200/JCO.2008.21.4163.CrossRefPubMed
20.
Bhargava R, Beriwal S, Dabbs DJ, Ozbek U, Soran A, Johnson RR, Brufsky AM, Lembersky BC, Ahrendt GM: Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases. Cancer. 2010, 116 (6): 1431-1439. 10.1002/cncr.24876.CrossRefPubMed
21.
Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, Gornbein J: Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer. 2010, 116 (18): 4227-4237. 10.1002/cncr.25309.CrossRefPubMed
22.
Chavez-Macgregor M, Litton J, Chen H, Giordano SH, Hudis CA, Wolff AC, Valero V, Hortobagyi GN, Bondy ML, Gonzalez-Angulo AM: Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity. Cancer. 2010, 116 (17): 4168-4177. 10.1002/cncr.25296.PubMedCentralCrossRefPubMed
23.
Chen XS, Wu JY, Huang O, Chen CM: Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy. Oncol Rep. 2010, 23: 1213-1220.PubMed
24.
Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, Belau A, Khandan F, Hauschild M, Thomssen C, Hogel B, Darb-Esfahani S, Mehta K, Loibl S: Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat. 2010, 124 (1): 133-140. 10.1007/s10549-010-1103-9.CrossRefPubMed
25.
Kim SI, Sohn J, Koo JS, Park SH, Park HS, Park BW: Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Oncology. 2010, 79 (5–6): 324-330.CrossRefPubMed
26.
Pierga JY, Delaloge S, Espie M, Brain E, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretiere JM, Spielmann M, Savignoni A, Marty M: A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat. 2010, 122 (2): 429-437. 10.1007/s10549-010-0939-3.CrossRefPubMed
27.
Straver ME, Rutgers EJ, Rodenhuis S, Linn SC, Loo CE, Wesseling J, Russell NS, Oldenburg HS, Antonini N, Vrancken Peeters MT: The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol. 2010, 17 (9): 2411-2418. 10.1245/s10434-010-1008-1.PubMedCentralCrossRefPubMed
28.
Bernsdorf M, Ingvar C, Jorgensen L, Tuxen MK, Jakobsen EH, Saetersdal A, Kimper-Karl ML, Kroman N, Balslev E, Ejlertsen B: Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial. Breast Cancer Res Treat. 2011, 126 (2): 463-470. 10.1007/s10549-011-1352-2.CrossRefPubMed
29.
Iwata H, Sato N, Masuda N, Nakamura S, Yamamoto N, Kuroi K, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Toi M: Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer. Jpn J Clin Oncol. 2011, 41 (7): 867-875. 10.1093/jjco/hyr081.CrossRefPubMed
30.
Loo CE, Straver ME, Rodenhuis S, Muller SH, Wesseling J, Vrancken Peeters MJ, Gilhuijs KG: Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol. 2011, 29 (6): 660-666. 10.1200/JCO.2010.31.1258.CrossRefPubMed
31.
Medioni J, Huchon C, Le Frere-Belda MA, Hofmann H, Bats AS, Eme D, Andrieu JM, Oudard S, Lecuru F, Levy E: Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors. Drugs R D. 2011, 11 (2): 147-157. 10.2165/11591210-000000000-00000.PubMedCentralCrossRefPubMed
32.
Nakahara H, Yasuda Y, Machida E, Maeda Y, Furusawa H, Komaki K, Funagayama M, Nakahara M, Tamura S, Akiyama F: MR and US imaging for breast cancer patients who underwent conservation surgery after neoadjuvant chemotherapy: comparison of triple negative breast cancer and other intrinsic subtypes. Breast Cancer. 2011, 18 (3): 152-160. 10.1007/s12282-010-0235-4.CrossRefPubMed
33.
Wu J, Li S, Jia W, Su F: Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer. J Cancer Res Clin Oncol. 2011, 137 (10): 1505-1510. 10.1007/s00432-011-1029-6.CrossRefPubMed
34.
Le Tourneau C, Dettwiler S, Beuzeboc P, Alran S, Laurence V, Pierga JY, Freneaux P, Sigal-Zafrani B, Dieras V, Vincent-Salomon A: Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer. Am J Clin Oncol. 2012, 35 (3): 242-246. 10.1097/COC.0b013e318209d34c.CrossRefPubMed
35.
Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, Hirata T, Yonemori K, Ando M, Tamura K, Katsumata N, Kinoshita T, Takiguchi Y, Tanzawa H, Fujiwara Y: Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2012, 132 (3): 793-805. 10.1007/s10549-011-1554-7.CrossRefPubMed
36.
Chavez-Macgregor M, Brown E, Lei X, Litton J, Meric-Bernstram F, Mettendorf E, Hernandez L, Valero V, Hortobagyi GN, Gonzalez-Angulo AM: Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer. Cancer. 2012, 118 (2): 326-332. 10.1002/cncr.26144.PubMedCentralCrossRefPubMed
37.
Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE: Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. 2010, 28 (7): 1145-1153. 10.1200/JCO.2009.22.4725.PubMedCentralCrossRefPubMed
38.
Koshy N, Quispe D, Shi R, Mansour R, Burton GV: Cisplatin-gemcitabine therapy in metastatic breast cancer: improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast. 2010, 19 (3): 246-248. 10.1016/j.breast.2010.02.003.CrossRefPubMed
39.
Chan D, Yeo WL, Tiemsim Cordero M, Wong CI, Chuah B, Soo R, Tan SH, Lim SE, Goh BC, Lee SC: Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes. Investig New Drugs. 2010, 28 (6): 859-865. 10.1007/s10637-009-9305-x.CrossRef
40.
Fan Y, Xu BH, Yuan P, Ma F, Wang JY, Ding XY, Zhang P, Li Q, Cai RG: Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Ann Oncol. 2013, 24 (5): 1219-1225. 10.1093/annonc/mds603.CrossRefPubMed
41.
Staudacher L, Cottu PH, Dieras V, Vincent-Salomon A, Guilhaume MN, Escalup L, Dorval T, Beuzeboc P, Mignot L, Pierga JY: Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol. 2011, 22 (4): 848-856. 10.1093/annonc/mdq461.CrossRefPubMed
42.
Uhm JE, Park YH, Yi SY, Cho EY, Choi YL, Lee SJ, Park MJ, Lee SH, Jun HJ, Ahn JS, Kang WK, Park K, Im YH: Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. Int J Cancer. 2009, 124 (6): 1457-1462. 10.1002/ijc.24090.CrossRefPubMed
43.
Nogi H, Kobayashi T, Suzuki M, Tabei I, Kawase K, Toriumi Y, Fukushima H, Uchida K: EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer. Oncol Rep. 2009, 21 (2): 413-417.PubMed
44.
Jones RL, Rojo F, A’Hern R, Villena N, Salter J, Corominas JM, Servitja S, Smith IE, Rovira A, Reis-Filho JS, Dowsett M, Albanell J: Nuclear NF-kappaB/p65 expression and response to neoadjuvant chemotherapy in breast cancer. J Clin Pathol. 2011, 64 (2): 130-135. 10.1136/jcp.2010.082966.CrossRefPubMed
45.
Chen XS, Nie XQ, Chen CM, Wu JY, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW: Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Ann Oncol. 2010, 21 (5): 961-967. 10.1093/annonc/mdq041.CrossRefPubMed
46.
Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer. 2007, 109 (9): 1721-1728. 10.1002/cncr.22618.CrossRefPubMed
47.
Bayraktar S, Gluck S: Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2013, 138 (1): 21-35. 10.1007/s10549-013-2421-5.CrossRefPubMed
48.
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature. 2000, 406 (6797): 747-752. 10.1038/35021093.CrossRefPubMed
49.
Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA, Ellis P, Di Leo A, Baselga J, Sotiriou C, Piccart-Gebhart M: Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol. 2012, 30 (15): 1879-1887. 10.1200/JCO.2011.38.2010.CrossRefPubMed
50.
Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO: Prognostic markers in triple-negative breast cancer. Cancer. 2007, 109 (1): 25-32. 10.1002/cncr.22381.CrossRefPubMed
51.
Weigelt B, Baehner FL, Reis-Filho JS: The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol. 2010, 220 (2): 263-280.PubMed
52.
Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008, 14 (5): 1368-1376. 10.1158/1078-0432.CCR-07-1658.CrossRefPubMed
53.
Penault-Llorca F, Viale G: Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective. Ann Oncol. 2012, 23 (Suppl 6): vi19-vi22.CrossRefPubMed
54.
Comen E, Davids M, Kirchhoff T, Hudis C, Offit K, Robson M: Relative contributions of BRCA1 and BRCA2 mutations to ‘triple-negative’ breast cancer in Ashkenazi women. Breast Cancer Res Treat. 2011, 129 (1): 185-190. 10.1007/s10549-011-1433-2.PubMedCentralCrossRefPubMed
55.
Lee E, McKean-Cowdin R, Ma H, Spicer DV, Van Den Berg D, Bernstein L, Ursin G: Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J Clin Oncol. 2011, 29 (33): 4373-4380. 10.1200/JCO.2010.33.6446.PubMedCentralCrossRefPubMed
56.
Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP: The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst. 2004, 96 (22): 1659-1668. 10.1093/jnci/djh312.CrossRefPubMed
57.
Foulkes WD, Smith IE, Reis-Filho JS: Triple-negative breast cancer. N Engl J Med. 2010, 363 (20): 1938-1948. 10.1056/NEJMra1001389.CrossRefPubMed
58.
Gelmon K, Dent R, Mackey JR, Laing K, McLeod D, Verma S: Targeting triple-negative breast cancer: optimising therapeutic outcomes. Ann Oncol. 2012, 23 (9): 2223-2234. 10.1093/annonc/mds067.CrossRefPubMed
59.
Martin M, Romero A, Cheang MC, Lopez Garcia-Asenjo JA, Garcia-Saenz JA, Oliva B, Roman JM, He X, Casado A, de la Torre J, Furio V, Puente J, Caldés T, Vidart JA, Lopez-Tarruella S, Diaz-Rubio E, Perou CM: Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. Breast Cancer Res Treat. 2011, 128 (1): 127-136. 10.1007/s10549-011-1461-y.CrossRefPubMed
60.
Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E: Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012, 48 (18): 3342-3354. 10.1016/j.ejca.2012.05.023.CrossRefPubMed
61.
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010, 134 (7): e48-e72.PubMed
Metadata
Title
Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy
Authors
Kunpeng Wu
Qiaozhu Yang
Yi Liu
Aibing Wu
Zhixiong Yang
Publication date
01-12-2014
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2014
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-12-95

Other articles of this Issue 1/2014

World Journal of Surgical Oncology 1/2014 Go to the issue

Research

Assessment of quality of life in giant ameloblastoma adolescent patients who have had mandible defects reconstructed with a free fibula flap

Case report

Malawer limb salvage surgery for the treatment of scapular chondrosarcoma

Case report

Diffuse filiform polyposis of the small intestine without inflammatory bowel disease

Case report

The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system

Research

Drug dosage in isolated limb perfusion: evaluation of a limb volume model for extremity volume calculation

Case report

A large esophageal gastrointestinal stromal tumor that was successfully resected after neoadjuvant imatinib treatment: case report